Diabetes Care, Vol 16, Issue 1 110-114, Copyright © 1993 by American Diabetes Association

ARTICLES

The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide

GS Meneilly, M Bryer-Ash and D Elahi
Department of Medicine, University of British Columbia, Vancouver, Canada.

OBJECTIVE--To assess whether treatment with glyburide alters beta-cell sensitivity to GIP in NIDDM patients. RESEARCH DESIGN AND METHODS--We studied 5 untreated NIDDM patients in a meal study (Ensure, 240 ml/M2) and a 2-h hyperglycemic glucose clamp study (glucose 5.4 mM above fasting). From 60 to 120 min of the clamp, GIP was infused in a primed continuous manner at a rate of 2 pmol.kg-1 x min-1. Subjects then were treated with glyburide. After they had been on a stable dose of medication for 1 mo, the meal study and glucose clamp studies were repeated. RESULTS--In response to treatment, a decrease in fasting glucose and an increase in weight was observed (12.8 +/- 1.8 vs. 8.5 +/- 0.8 mM and 74.3 +/- 6.3 vs. 76.1 +/- 6.3 kg, respectively, P < 0.05). In response to the meal study, the AUC for glucose was less, for insulin was increased, and for GIP was unchanged after treatment (16.9 +/- 2.1 vs. 12.6 +/- 6.9 mM, P < 0.05; 161 +/- 47 vs. 242 +/- 60 pM, P < 0.05; and 199 +/- 22 vs. 219 +/- 18 pM, respectively). During the hyperglycemic clamp, steady-state glucose and 90- to 120-min GIP values were equivalent before and after treatment (18.0 +/- 1.3 vs. 18.3 +/- 1.3 mM and 302 +/- 59 vs. 298 +/- 37 pM, respectively). The 90-120 min insulin responses to the hyperglycemic clamp were greater after therapy (123 +/- 37 vs. 283 +/- 80 pM, P < 0.05) reflecting increased beta-cell responses to GIP. CONCLUSIONS--We conclude that glyburide enhances beta-cell sensitivity to GIP.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. A. Hinke, S. Manhart, K. Kuhn-Wache, C. Nian, H.-U. Demuth, R. A. Pederson, and C. H. S. McIntosh [Ser2]- and [Ser(P)2]Incretin Analogs: COMPARISON OF DIPEPTIDYL PEPTIDASE IV RESISTANCE AND BIOLOGICAL ACTIVITIES IN VITRO AND IN VIVO J. Biol. Chem., February 6, 2004; 279(6): 3998 - 4006. [Abstract] [Full Text] [PDF]

				D. J. Drucker Enhancing Incretin Action for the Treatment of Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2929 - 2940. [Abstract] [Full Text] [PDF]

				S. A. Hinke, R. W. Gelling, R. A. Pederson, S. Manhart, C. Nian, H.-U. Demuth, and C. H.S. McIntosh Dipeptidyl Peptidase IV-Resistant [D-Ala2]Glucose-Dependent Insulinotropic Polypeptide (GIP) Improves Glucose Tolerance in Normal and Obese Diabetic Rats Diabetes, March 1, 2002; 51(3): 652 - 661. [Abstract] [Full Text] [PDF]

				J. Korosi, C. H.S. McIntosh, R. A. Pederson, H.-U. Demuth, J. F. Habener, R. Gingerich, J. M. Egan, D. Elahi, and G. S. Meneilly Effect of Aging and Diabetes on the Enteroinsular Axis J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2001; 56(9): M575 - 579. [Abstract] [Full Text] [PDF]

				H. Kindmark, J. Pigon, and S. Efendic Glucose-Dependent Insulinotropic Hormone Potentiates the Hypoglycemic Effect of Glibenclamide in Healthy Volunteers: Evidence for an Effect on Insulin Extraction J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2015 - 2019. [Abstract] [Full Text]